Treatment.com AI Provides an Update on the Status of Exercised Warrants
24 July 2024 - 8:00AM
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the
“
Company” or “
Treatment”), a healthcare tech company
transforming patient care with AI-driven clinical insights is
pleased to provide the market with an update on the exercising of
the warrants which were issued upon conversion of the special
warrants on June 21, 2024.
Since the special warrant conversion, the Company is thrilled to
announce that almost 800,000 warrants have been exercised raising
gross proceeds approximating to half a million dollars.
Dr. Essam Hamza, CEO of Treatment.com AI, comments: “These
warrant exercises underscore the strong investor support for our
company. The cash injection enables us to expedite our plans at a
time when both the investor and healthcare markets are looking for
credible AI solutions to mitigate the challenges faced by our
healthcare systems. Apart from our previously announced plans to
launch our “AI Patient” and “AI Doctor in the Pocket'' products
this fall, we also have a strong acquisition pipeline under review
that could provide an accelerated timeline for our growth strategy.
We look forward to the exercising of the remaining warrants which
could bring another $2 Million injection to the treasury.”
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI to positively disrupt
the healthcare sector and impact current inefficiencies and
challenges. Over the past 7+ years and with the input of hundreds
of healthcare professionals globally, Treatment.com AI has built
the world’s most intelligent, personalized healthcare AI engine,
the Global Library of Medicine (GLM). Providing the highest
qualified clinical information and support to all healthcare
professionals, the GLM delivers >92%+ accuracy on first
diagnosis as well as providing recommended tests (physical and
lab), x-rays, and billing codes. The platform’s quality and
transparency are unrivaled, as the GLM provides an explanation of
every step and likelihood associated with every symptom.
Treatment.com AI also focuses on the next generation of healthcare
professionals supporting Medical and Nursing schools, who utilize
the GLM to help enhance the future clinical skills of their
students. Treatment.com AI is focused on using AI for good and
utilizing its GLM platform to bring the possibility of health
equity and inclusion for disenfranchised communities.
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
ehamza@treatment.com
If you would like to find out more about Treatment’s products
and services, please email at info@treatment.com
For media inquiries, contact: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888)
788-8955
Cautionary Statements
This news release contains forward-looking statements that are
based on Treatment.com AI’s expectations, estimates and projections
regarding its business and the economic environment in which it
operates, including with respect to the implementation of its
shareholder communications initiative and the timing thereof.
Although Treatment.com believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and
involve risks and uncertainties that are difficult to control or
predict. Therefore, actual outcomes and results may differ
materially from those expressed in these forward-looking
statements, and readers should not place undue reliance on such
statements. These forward-looking statements speak only as of the
date on which they are made, and Treatment.com undertakes no
obligation to update them publicly to reflect new information or
the occurrence of future events or circumstances unless otherwise
required to do so by law.
The Canadian Securities Exchange does not accept responsibility
for the adequacy or accuracy of this release.